There is an axsm thread.....
Subject 59828
Stunned. Bought a few shares just before the close, figuring that cheaper shares would soon be available. Then went to track for hurdles practice. Came back to this......
axsometherapeuticsinc.gcs-web.com[min]=2019
Keep looking for any sign of a typo. Can't find one. These guys/gals sold into today's news, average selling price of $8.08/share, to address a major shortage of cash. There will also be warrants coming in.
Intraday high was $8.89. Closed regular trading at around $6.88. Then the funding news came out. Closed after-hours at $7.59. Closed Friday at $2.63.
>> ASCEND (Assessing Clinical Episodes in Depression) is a Phase 2, randomized, double-blind, active-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD) conducted in the United States. A total of 80 patients with a diagnosis of moderate to severe MDD, confirmed by an independent clinical assessor, were randomized in a 1:1 ratio to receive AXS-05 (45 mg dextromethorphan/105 mg bupropion) (n=43), or bupropion (105 mg) (n=37), twice daily for 6 weeks. Prespecified efficacy analyses were conducted on this population on an intent-to-treat basis. The mean Montgomery-Åsberg Depression Rating Scale (MADRS) total scores at baseline were 31.8 for the AXS-05 group and 32.2 for the bupropion group. The study incorporated comprehensive blinding of investigators and patients to the confirmation of diagnosis. Patients without a confirmed diagnosis of moderate to severe MDD but who met all other entry criteria (n=17) were randomized for assessment of safety to maintain the blinding of study investigators, as prespecified. The prespecified primary endpoint of the study was the change from baseline in the MADRS total score, calculated at each time point in the study and averaged (overall treatment effect). Secondary endpoints included MADRS-6, Clinical Global Impression-Improvement (CGI-I), Clinical Global Impression-Severity (CGI-S), remission, safety and tolerability. << |
